6 O
ADVERSE O
REACTIONS O
Clinically O
significant O
adverse O
reactions O
that O
appear O
in O
other O
sections O
of O
the O
labeling O
include O
: O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hemoglobin I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
more O
frequent O
than O
placebo O
by O
> O
=3 O
% O
) O
are O
anemia O
, O
nasopharyngitis/pharyngitis O
, O
bronchitis O
, O
headache O
, O
influenza O
, O
and O
urinary O
tract O
infection O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Actelion O
at O
1-866-228-3546 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Safety O
data O
for O
OPSUMIT O
were O
obtained O
primarily O
from O
one O
placebo-controlled O
clinical O
study O
in O
742 O
patients O
with O
PAH B-Not_AE_Candidate
( O
SERAPHIN O
study O
) O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
exposure O
to O
OPSUMIT O
in O
this O
trial O
was O
up O
to O
3.6 O
years O
with O
a O
median O
exposure O
of O
about O
2 O
years O
( O
N=542 O
for O
1 O
year O
; O
N=429 O
for O
2 O
years O
; O
and O
N=98 O
for O
more O
than O
3 O
years O
) O
. O

The O
overall O
incidence O
of O
treatment O
discontinuations O
because O
of O
adverse O
events O
was O
similar O
across O
OPSUMIT O
10 O
mg O
and O
placebo O
treatment O
groups O
( O
approximately O
11 O
% O
) O
. O

Table O
2 O
presents O
adverse O
reactions O
more O
frequent O
on O
OPSUMIT O
than O
on O
placebo O
by O
> O
=3 O
% O
. O

Table O
2 O
Adverse O
Reactions O
Adverse O
Reaction O
OPSUMIT O
10 O
mg O
( O
N=242 O
) O
( O
% O
) O
Placebo O
( O
N=249 O
) O
( O
% O
) O
Anemia B-OSE_Labeled_AE
13 O
3 O
Nasopharyngitis B-OSE_Labeled_AE
/ O
pharyngitis B-OSE_Labeled_AE
20 O
13 O
Bronchitis B-OSE_Labeled_AE
12 O
6 O
Headache B-OSE_Labeled_AE
14 O
9 O
Influenza B-OSE_Labeled_AE
6 O
2 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
9 O
6 O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
OPSUMIT O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
angioedema B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
and O
rash B-OSE_Labeled_AE
) O
Respiratory B-NonOSE_AE
, O
thoracic O
and O
mediastinal O
disorders I-NonOSE_AE
: O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE

